GenCore version 5.1.4_p5_4578

OM nucleic - nucleic search, using sw model

Run on: March 10, 2003, 21:31:17 ; Search time 142.984 Seconds
(without alignments)
488.248 Million cell updates/sec

Title: US-09-913-524-34
Perfect score: 31
Sequence: 1 atcattgctccctctggctatcatgccaact 31

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	31	100.0	405	24	ABL64291	Stomach cancer rel
	2	31	100.0	425	7	AAN60429	Sequence encoding
	3	31	100.0	1620	22	AAH57530	Human pancreas cel
	4	31	100.0	1630	8	AAN70315	Sequence encoding
	5	31	100.0	1700	22	AAS06008	Angiotensin conver
	6	31	100.0	1873	11	AAQ01648	BUF-3 gene for hum
	7	31	100.0	4068	24	ABL62912	Breast cancer rela
	8	31	100.0	4068	24	ABL63117	Breast cancer rela
	9	31	100.0	4068	24	ABL64417	Stomach cancer rel
	10	31	100.0	14416	22	AAL05491	Human reproductive
	11	31	100.0	14416	23	ABL98344	Human testicular a
	12	26.2	84.5	958	7	AAN60427	Sequence encoding
	13	23	74.2	3588	8	AAN70317	Sequence encoding
	14	21.4	69.0	1667	12	AAQ10890	Encodes Xenopus Bo
	15	20.6	66.5	9662	22	AAL07086	Human reproductive
	16	20.6	66.5	17705	22	AAL07085	Human reproductive
	17	19.8	63.9	406	16	AAQ89258	BMP-6 encoding DNA
	18	19.8	63.9	406	19	AAV24032	Bone morphogenetic
	19	19.8	63.9	497	20	AAV99382	cDNA encoding bone
	20	19.8	63.9	894	13	AAQ23678	Encodes C-terminal
	21	19.8	63.9	894	14	AAQ37567	BMP-6 coding seque
	22	19.8	63.9	894	20	AAX99261	DNA encoding carbo
	23	19.8	63.9	1350	22	AAH76483	BMP 7/6 glu nucleo
	24	19.8	63.9	1353	22	AAH76484	BMP 7/6 myc nucleo
	25	19.8	63.9	1362	22	AAH76481	BMP 4/6 glu nucleo
	26	19.8	63.9	2385	23	AAS65056	DNA encoding novel
	27	19.8	63.9	2385	23	AAS78659	DNA encoding novel
	28	19.8	63.9	2385	23	AAS81638	DNA encoding novel
	29	19.8	63.9	2471	23	AAS71026	DNA encoding novel
	30	19.8	63.9	2923	11	AAQ06173	Human Bone Morphog
	31	19.8	63.9	2923	13	AAQ32855	BMP6. Rattus ratt
	32	19.8	63.9	2923	14	AAQ37568	Human BMP-6 coding
	33	19.8	63.9	2923	14	AAQ41294	Human BMP-6 gene.
	34	19.8	63.9	3184	23	AAS87074	DNA encoding novel
	35	19.8	63.9	5651	21	AAC77516	Human ORFX ORF3071
	36	19.8	63.9	5801	22	AAS22778	Human cDNA encodin
c	37	19.8	63.9	31169	22	AAS41761	Genomic sequence #
c	38	19.8	63.9	31169	22	AAK75191	Human immune/haema
c	39	19.8	63.9	31169	23	ABK44029	Genomic DNA encodi
	40	19.6	63.2	167343	24	ABL64403	Stomach cancer rel
	41	19.6	63.2	167343	24	ABL67239	Thyroid cancer rel
c	42	19	61.3	1548	19	AAV66850	Chlamydia 16S ribo
c	43	19	61.3	2493	23	AAS88122	DNA encoding novel
	44	19	61.3	5741	12	AAQ14939	Bacterial amylase
	45	18.8	60.6	99	16	AAQ82942	Partial coding seq

ALIGNMENTS

RESULT 1
ABL64291/c
ID ABL64291 standard; DNA; 405 BP.
XX
AC ABL64291;
XX
DT 15-MAY-2002 (first entry)
XX
DE Stomach cancer related gene sequence SEQ ID NO:2628.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.

PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235134P.
PR 25-SEP-2000; 2000US-235280P.
PR 26-SEP-2000; 2000US-235637P.
PR 26-SEP-2000; 2000US-235638P.
PR 27-SEP-2000; 2000US-235711P.
PR 27-SEP-2000; 2000US-235720P.
PR 27-SEP-2000; 2000US-235840P.
PR 27-SEP-2000; 2000US-235863P.
PR 28-SEP-2000; 2000US-236028P.
PR 28-SEP-2000; 2000US-236032P.
PR 28-SEP-2000; 2000US-236033P.
PR 28-SEP-2000; 2000US-236034P.
PR 28-SEP-2000; 2000US-236109P.
PR 28-SEP-2000; 2000US-236111P.
PR 29-SEP-2000; 2000US-236842P.
PR 29-SEP-2000; 2000US-236891P.
PR 02-OCT-2000; 2000US-237172P.
PR 02-OCT-2000; 2000US-237173P.
PR 02-OCT-2000; 2000US-237278P.
PR 02-OCT-2000; 2000US-237294P.
PR 02-OCT-2000; 2000US-237295P.
PR 02-OCT-2000; 2000US-237316P.
PR 03-OCT-2000; 2000US-237425P.
PR 03-OCT-2000; 2000US-237598P.
PR 03-OCT-2000; 2000US-237604P.
PR 03-OCT-2000; 2000US-237606P.
PR 03-OCT-2000; 2000US-237608P.
PR 01-NOV-2000; 2000US-244867P.
PR 01-NOV-2000; 2000US-245084P.
XX
PA (AVAL-) AVALON PHARM.
XX
PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX
DR WPI; 2002-188264/24.
XX
PT Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set -
XX
PS Claim 1; SEQ ID 2628; 44pp; English.
XX
CC The present invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilm's tumour.
XX
SQ Sequence 405 BP; 88 A; 97 C; 98 G; 121 T; 1 other;

Query Match 100.0%; Score 31; DB 24; Length 405;
Best Local Similarity 100.0%; Pred. No. 0.00069;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 384 ATCATTGCTCCCTCTGGCTATCATGCCAACT 354

RESULT 2
AAN60429
ID AAN60429 standard; cDNA; 425 BP.
XX
AC AAN60429;
XX
DT 26-JUN-1991 (first entry)
XX
DE Sequence encoding human inhibin B subunit.
XX
KW Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..42
FT /*tag= a
FT mat_peptide 43..393
FT /*tag= b
XX
PN WO8606076-A.
XX
PD 23-OCT-1986.
XX
PF 14-APR-1986; 86WO-AU00097.
XX
PR 20-DEC-1985; 85AU-0003961.
PR 18-APR-1985; 85AU-0000194.
PR 06-SEP-1985; 85AU-0002320.
PR 29-OCT-1985; 85AU-0003157.
PR 19-DEC-1985; 85AU-0003960.
PR 01-JAN-1986; 86AU-0059039.
PR 02-APR-1987; 87AU-0071015.
PR 05-MAY-1986; 86CN-0103459.
XX
PA (BIOT-) BIOTECHN AUSTR PTY.
PA (MONU) MONASH UNIV.
PA (HENR-) PRICE HENRY'S HOSPITAL.
PA (SVIN-) ST VINCENTS'S INST MED RE.
XX
PI Forage R, Stewart A, Robertson D, Dekretser DM;
XX
DR WPI; 1986-291647/44.
DR P-PSDB; AAP60520.
XX
PT New polynucleotide sequences and recombinant DNA - encoding
PT inhibin and synthetic peptides useful for affecting gonadal
PT function
XX
PS Claim 8; Fig 8; 71pp; English.
XX
CC DNA encoding inhibin and inhibin or part, analogues, homologues or
CC precursors thereof when produced by recombinant techniques are also
CC claimed, as well as pharmaceutical compositions thereof. These may
CC be used as an inhibin agonist, antagonist or for eliciting an
CC antigenic response to affect gonadal function or reproductive
CC physiology.
XX
SQ Sequence 425 BP; 103 A; 116 C; 115 G; 91 T; 0 other;

Query Match 100.0%; Score 31; DB 7; Length 425;
Best Local Similarity 100.0%; Pred. No. 0.00069;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 127 ATCATTGCTCCCTCTGGCTATCATGCCAACT 157

RESULT 3

```
AAH57530
ID   AAH57530 standard; cDNA; 1620 BP.
XX
AC   AAH57530;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human pancreas cell specific cDNA sequence SEQ ID NO:370.
XX
KW   Human; tissue specific; diagnosis; brain; heart; skeletal muscle;
KW   lung; liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss;
KW   metabolic disease; developmental disease; cytostatic; immunomodulatory;
KW   neuroprotective; gene therapy; cancer; immunopathology; neuropathology.
XX
OS   Homo sapiens.
XX
PN   WO200132927-A2.
XX
PD   10-MAY-2001.
XX
PF   02-NOV-2000; 2000WO-US30396.
XX
PR   04-NOV-1999;   99US-0163508.
XX
PA   (INCY-) INCYTE GENOMICS INC.
XX
PI   Sornasse T,  Seilhamer JJ,  Watson GA;
XX
DR   WPI; 2001-291057/30.
XX
PT   New cell and tissue specific polynucleotides useful for diagnosis,
PT   prognosis or monitoring of treatments for disorders where the gene is
PT   associated with a cancer, immunopathology or neuropathology -
XX
PS   Claim 1; Page 287-288; 327pp; English.
XX
CC   AAH57161 to AAH57576 represent cell and tissue specific polynucleotide
CC   sequences (I). (I) can have cytostatic, immunomodulatory and
CC   neuroprotective activities, and can be used in gene therapy. (I) and
CC   proteins (II) encoded by then are used in high throughput screening
CC   assays to select DNA molecules, RNA molecules, peptide nucleic acids,
CC   mimetics, peptides, proteins, agonists, antagonists, antibodies or
CC   their fragments, immunoglobulins, inhibitors, drug compounds and
CC   pharmaceutical agents. Expression of (I) in a sample indicates the
CC   differentiation of embryonic stem cells into a tissue selected from
CC   brain, heart, kidney, liver, lung, skeletal muscle or pancreatic
CC   tissues. (I) and (II) are used to produce an expression profile that
CC   defines a metabolic or developmental process, treatment, condition,
CC   disease or disorder. The gene profile can be used for diagnosis,
CC   prognosis or monitoring of treatments and for investigating a
CC   predisposition to a disorder where the gene is associated with a
CC   cancer, immunopathology or neuropathology.
XX
SQ   Sequence 1620 BP; 475 A; 377 C; 476 G; 291 T; 1 other;

  Query Match             100.0%;  Score 31;  DB 22;  Length 1620;
  Best Local Similarity   100.0%;  Pred. No. 0.00086;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
           |||||||||||||||||||||||||||||||
Db    1230 ATCATTGCTCCCTCTGGCTATCATGCCAACT 1260


RESULT 4
AAN70315
ID   AAN70315 standard; cDNA; 1630 BP.
XX
AC   AAN70315;
XX
DT   09-APR-1991  (first entry)
XX
DE   Sequence encoding human inhibin beta-chain precursor beta-A.
XX
KW   Fertility control; contraception; hormone; spermatogenesis; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             37..320
FT                   /*tag= a
FT                   /product=signal sequence
FT   CDS             321..1166
FT                   /*tag= b
FT                   /product=pro region
FT   mat_peptide     1167..1517
FT                   /*tag= c
XX
PN   EP222491-A.
XX
PD   20-MAY-1987.
XX
PF   02-OCT-1986;   86EP-0307586.
XX
PR   12-SEP-1986;   86US-0906729.
PR   03-OCT-1985;   85US-0783910.
PR   10-FEB-1986;   86US-0827710.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Mason AJ,  Seeburg PH;
XX
DR   WPI; 1987-137512/20.
DR   P-PSDB; AAP70203.
XX
PT   Recombinant human or porcine inhibin or activin - used for
PT   modulating clinical condition or reproductive physiology of
PT   animals.
XX
PS   Disclosure; Fig 8A; 48pp; English.
XX
CC   A compsn. comprising human or porcine inhibin which is completely
CC   free of unidentified or porcine proteins is claimed.  Also claimed
CC   are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
CC   chain.  Sequencing of inhibin-encoding cDNA has led to the
CC   identification of prodomain regions located N terminal to the
CC   mature inhibin chains that represent coordinately expressed
CC   biologically active polypeptides.  The prodomain regions or
CC   prodomain immunogens are useful in monitoring preproinhibin
CC   processing in transformant cell culture or in experiments directed
CC   at modulating the clinical condt. or reproductive physiology of
CC   animals.
XX
SQ   Sequence 1630 BP; 472 A; 390 C; 466 G; 302 T; 0 other;

  Query Match             100.0%;  Score 31;  DB 8;  Length 1630;
  Best Local Similarity   100.0%;  Pred. No. 0.00086;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
           |||||||||||||||||||||||||||||||
Db    1251 ATCATTGCTCCCTCTGGCTATCATGCCAACT 1281


RESULT 5
AAS06008
ID   AAS06008 standard; DNA; 1700 BP.
XX
AC   AAS06008;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Angiotensin converting enzyme (ACEV) splice variant DNA #8.
XX
KW   Angiotensin converting enzyme splice variant; ACEV; interleukin 6;
KW   granulocyte colony stimulating factor receptor; glucagon; hypertrophy;
```

KW platelet-derived endothelial cell growth factor; cardiovascular disease;
KW cellular tumour antigen P53; cyclin-dependent kinase inhibitor 1C; ds;
KW vasoactive intestinal polypeptide receptor 2; arteriosclerosis; cancer;
KW myocardial infarction; coronary arterial thrombosis; renal disease;
KW diabetic nephropathy; muscular disease; immune disorder; sarcoidosis;
KW multiple sclerosis; immune complex nephritis; deep vein thrombosis;
KW nonarcoidotic pulmonary granulomatous disease; endothelial abnormality;
KW vascular disorder; asbestosis.
XX
OS Homo sapiens.
XX
PN WO200136632-A2.
XX
PD 25-MAY-2001.
XX
PF 17-NOV-2000; 2000WO-IL00766.
XX
PR 17-NOV-1999; 99IL-0132978.
PR 10-DEC-1999; 99IL-0133455.
XX
PA (COMP-) COMPUGEN LTD.
XX
PI Levine Z, David A, Azar I, Khosravi R, Bernstein J;
XX
DR WPI; 2001-336004/35.
DR P-PSDB; AAU02908.
XX
PT Novel alternative splicing variants e.g. variant of angiotensin
PT converting enzyme (ACEV), useful in identifying candidate compounds
PT capable of binding to the variant and to detect anti-variant antibodies
PT -
XX
PS Claim 1; Page 319; 519pp; English.
XX
CC The sequence represents a DNA encoding an angiotensin converting enzyme
CC splice variant (ACEV) polypeptide. The polypeptides of the invention
CC include variants of granulocyte colony stimulating factor receptor,
CC glucagon, interleukin 6, platelet-derived endothelial cell growth factor,
CC cyclin-dependent kinase inhibitor 1C, cellular tumour antigen P53, and
CC vasoactive intestinal polypeptide receptor 2. The polypeptides and their
CC associated nucleic acids are useful for identification of variant
CC sequences and detection of candidate compounds capable of binding the
CC molecules. The sequences of the invention can be used in the treatment
CC and diagnosis of various disorders including cardiovascular diseases such
CC as arteriosclerosis, myocardial infarction and coronary arterial
CC thrombosis, renal diseases such as diabetic nephropathy, muscular
CC diseases such as hypertrophy, immune disorders such as immune complex
CC nephritis, multiple sclerosis, cancer, sarcoidosis, nonarcoidotic
CC pulmonary granulomatous diseases such as asbestosis and vascular
CC pathologies involving an endothelial abnormality such as deep vein
CC thrombosis.
XX
SQ Sequence 1700 BP; 509 A; 387 C; 440 G; 362 T; 2 other;

Query Match 100.0%; Score 31; DB 22; Length 1700;
Best Local Similarity 100.0%; Pred. No. 0.00087;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 820 ATCATTGCTCCCTCTGGCTATCATGCCAACT 850

RESULT 6
AAQ01648
ID AAQ01648 standard; DNA; 1873 BP.
XX
AC AAQ01648;
XX
DT 27-JUL-1990 (first entry)
XX
DE BUF-3 gene for human differentiation inducing factor.
XX
KW BUF-3; dhfr; dihydrofolic acid reductase; differentiation.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 119..1397
FT /*tag= a
FT misc_RNA 983..1397
FT /*tag= b
FT /label=BUF-3 subunit
XX
PN JP02009388-A.
XX
PD 12-JAN-1990.
XX
PF 08-JUL-1988; 88JP-0170142.
XX
PR 09-MAR-1988; 88JP-0055270.
XX
PA (AJIN) AJINOMOTO KK.
XX
DR WPI; 1990-055348/08.
DR P-PSDB; AAR05413.
XX
PT Physiologically active protein prepn. -
PT by transforming plasmid having gene coding physiologically
PT active protein and gene of di:hydrofolic acid reductase to hamster
PT ovary etc.
XX
PS Example 1; Fig 1; 12pp; Japanese.
XX
CC Gene may be expressed by transforming a dhfr negative strain of CHO cells
CC with an active BUF-3 gene and dhfr carrying vector. The BUF-3 gene is
CC a cell differentiating factor.
XX
SQ Sequence 1873 BP; 566 A; 431 C; 520 G; 356 T; 0 other;

Query Match 100.0%; Score 31; DB 11; Length 1873;
Best Local Similarity 100.0%; Pred. No. 0.00088;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 1133 ATCATTGCTCCCTCTGGCTATCATGCCAACT 1163

RESULT 7
ABL62912
ID ABL62912 standard; DNA; 4068 BP.
XX
AC ABL62912;
XX
DT 15-MAY-2002 (first entry)
XX
DE Breast cancer related gene sequence SEQ ID NO:1249.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.

PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235134P.
PR 25-SEP-2000; 2000US-235280P.
PR 26-SEP-2000; 2000US-235637P.
PR 26-SEP-2000; 2000US-235638P.
PR 27-SEP-2000; 2000US-235711P.
PR 27-SEP-2000; 2000US-235720P.
PR 27-SEP-2000; 2000US-235840P.
PR 27-SEP-2000; 2000US-235863P.
PR 28-SEP-2000; 2000US-236028P.
PR 28-SEP-2000; 2000US-236032P.
PR 28-SEP-2000; 2000US-236033P.
PR 28-SEP-2000; 2000US-236034P.
PR 28-SEP-2000; 2000US-236109P.
PR 28-SEP-2000; 2000US-236111P.
PR 29-SEP-2000; 2000US-236842P.
PR 29-SEP-2000; 2000US-236891P.
PR 02-OCT-2000; 2000US-237172P.
PR 02-OCT-2000; 2000US-237173P.
PR 02-OCT-2000; 2000US-237278P.
PR 02-OCT-2000; 2000US-237294P.
PR 02-OCT-2000; 2000US-237295P.
PR 02-OCT-2000; 2000US-237316P.
PR 03-OCT-2000; 2000US-237425P.
PR 03-OCT-2000; 2000US-237598P.
PR 03-OCT-2000; 2000US-237604P.
PR 03-OCT-2000; 2000US-237606P.
PR 03-OCT-2000; 2000US-237608P.
PR 01-NOV-2000; 2000US-244867P.
PR 01-NOV-2000; 2000US-245084P.
XX
PA (AVAL-) AVALON PHARM.
XX
PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX
DR WPI; 2002-188264/24.
XX
PT Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set -
XX
PS Claim 1; SEQ ID 1249; 44pp; English.
XX
CC The present invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilm's tumour.
XX
SQ Sequence 4068 BP; 1291 A; 744 C; 893 G; 1140 T; 0 other;

Query Match 100.0%; Score 31; DB 24; Length 4068;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 1093 ATCATTGCTCCCTCTGGCTATCATGCCAACT 1123

RESULT 8
ABL63117
ID ABL63117 standard; DNA; 4068 BP.
XX
AC ABL63117;
XX
DT 15-MAY-2002 (first entry)
XX
DE Breast cancer related gene sequence SEQ ID NO:1454.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235134P.
PR 25-SEP-2000; 2000US-235280P.
PR 26-SEP-2000; 2000US-235637P.
PR 26-SEP-2000; 2000US-235638P.
PR 27-SEP-2000; 2000US-235711P.
PR 27-SEP-2000; 2000US-235720P.
PR 27-SEP-2000; 2000US-235840P.
PR 27-SEP-2000; 2000US-235863P.
PR 28-SEP-2000; 2000US-236028P.
PR 28-SEP-2000; 2000US-236032P.
PR 28-SEP-2000; 2000US-236033P.
PR 28-SEP-2000; 2000US-236034P.
PR 28-SEP-2000; 2000US-236109P.
PR 28-SEP-2000; 2000US-236111P.
PR 29-SEP-2000; 2000US-236842P.
PR 29-SEP-2000; 2000US-236891P.
PR 02-OCT-2000; 2000US-237172P.
PR 02-OCT-2000; 2000US-237173P.
PR 02-OCT-2000; 2000US-237278P.
PR 02-OCT-2000; 2000US-237294P.
PR 02-OCT-2000; 2000US-237295P.
PR 02-OCT-2000; 2000US-237316P.
PR 03-OCT-2000; 2000US-237425P.
PR 03-OCT-2000; 2000US-237598P.
PR 03-OCT-2000; 2000US-237604P.
PR 03-OCT-2000; 2000US-237606P.
PR 03-OCT-2000; 2000US-237608P.
PR 01-NOV-2000; 2000US-244867P.
PR 01-NOV-2000; 2000US-245084P.

XX
PA (AVAL-) AVALON PHARM.
XX
PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX
DR WPI; 2002-188264/24.
XX
PT Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set -
XX
PS Claim 1; SEQ ID 1454; 44pp; English.
XX
CC The present invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilm's tumour.
XX
SQ Sequence 4068 BP; 1291 A; 744 C; 893 G; 1140 T; 0 other;

Query Match 100.0%; Score 31; DB 24; Length 4068;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 1093 ATCATTGCTCCCTCTGGCTATCATGCCAACT 1123

RESULT 9
ABL64417
ID ABL64417 standard; DNA; 4068 BP.
XX
AC ABL64417;
XX
DT 15-MAY-2002 (first entry)
XX
DE Stomach cancer related gene sequence SEQ ID NO:2754.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235134P.
PR 25-SEP-2000; 2000US-235280P.
PR 26-SEP-2000; 2000US-235637P.
PR 26-SEP-2000; 2000US-235638P.
PR 27-SEP-2000; 2000US-235711P.
PR 27-SEP-2000; 2000US-235720P.
PR 27-SEP-2000; 2000US-235840P.
PR 27-SEP-2000; 2000US-235863P.
PR 28-SEP-2000; 2000US-236028P.
PR 28-SEP-2000; 2000US-236032P.
PR 28-SEP-2000; 2000US-236033P.
PR 28-SEP-2000; 2000US-236034P.
PR 28-SEP-2000; 2000US-236109P.
PR 28-SEP-2000; 2000US-236111P.
PR 29-SEP-2000; 2000US-236842P.
PR 29-SEP-2000; 2000US-236891P.
PR 02-OCT-2000; 2000US-237172P.
PR 02-OCT-2000; 2000US-237173P.
PR 02-OCT-2000; 2000US-237278P.
PR 02-OCT-2000; 2000US-237294P.
PR 02-OCT-2000; 2000US-237295P.
PR 02-OCT-2000; 2000US-237316P.
PR 03-OCT-2000; 2000US-237425P.
PR 03-OCT-2000; 2000US-237598P.
PR 03-OCT-2000; 2000US-237604P.
PR 03-OCT-2000; 2000US-237606P.
PR 03-OCT-2000; 2000US-237608P.
PR 01-NOV-2000; 2000US-244867P.
PR 01-NOV-2000; 2000US-245084P.
XX
PA (AVAL-) AVALON PHARM.
XX
PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
PI Soppet DR, Weaver Z;
XX
DR WPI; 2002-188264/24.
XX
PT Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set -
XX
PS Claim 1; SEQ ID 2754; 44pp; English.
XX
CC The present invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (I) of a signature gene set, where (I)
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
CC to ABL70110), or is at least 95% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilm's tumour.
XX
SQ Sequence 4068 BP; 1291 A; 744 C; 893 G; 1140 T; 0 other;

Query Match 100.0%; Score 31; DB 24; Length 4068;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
          ||||||||||||||||||||||||||||||
Db   1093 ATCATTGCTCCCTCTGGCTATCATGCCAACT 1123


RESULT 10
AAL05491
ID   AAL05491 standard; DNA; 14416 BP.
XX
AC   AAL05491;
XX
DT   21-NOV-2001  (first entry)
XX
DE   Human reproductive system related antigen DNA SEQ ID NO: 8179.
XX
KW   Human; reproductive system related antigen; reproductive system disorder;
KW   cancer; gene therapy; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155320-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01339.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
```

PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 8179; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 14416 BP; 4206 A; 3105 C; 3196 G; 3909 T; 0 other;

Query Match 100.0%; Score 31; DB 22; Length 14416;
Best Local Similarity 100.0%; Pred. No. 0.0012;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 13179 ATCATTGCTCCCTCTGGCTATCATGCCAACT 13209

RESULT 11
ABL98344
ID ABL98344 standard; DNA; 14416 BP.
XX
AC ABL98344;
XX
DT 21-JUN-2002 (first entry)
XX
DE Human testicular antigen encoding DNA fragment SEQ ID NO: 2996.
XX
KW Human; testicular antigen; testes; cancer; metastasis; immune disorder;
KW reproductive system disorder; urinary system disorder; gene therapy;
KW cardiovascular disorder; respiratory disorder; neurological disorder;
KW gastrointestinal disease; infection; cytostatic; gene; ds.
XX
OS Homo sapiens.
XX
PN WO200155317-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01329.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.

PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483232/52.
XX
PT Nucleic acids encoding 973 human testicular antigen polypeptides,
PT useful for preventing, diagnosing and/or treating testicular cancer
XX
PS Disclosure; SEQ ID NO 2996; 766pp; English.
XX
CC The present invention provides the protein and coding sequences of 973
CC human testicular antigens, and fragments of their genomic sequences. The
CC sequences can be used in the treatment of cardiovascular, urinary system,
CC reproductive system, immune, respiratory, neurological and
CC gastrointestinal disorders, infections, and particularly cancer,
CC especially testicular cancers. The present sequence is a DNA encoding a
CC protein fragment of the invention.
XX
SQ Sequence 14416 BP; 4206 A; 3105 C; 3196 G; 3909 T; 0 other;

Query Match 100.0%; Score 31; DB 23; Length 14416;
Best Local Similarity 100.0%; Pred. No. 0.0012;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
||||||||||||||||||||||||||||||
Db 13179 ATCATTGCTCCCTCTGGCTATCATGCCAACT 13209

RESULT 12
AAN60427
ID AAN60427 standard; cDNA; 958 BP.
XX
AC AAN60427;
XX
DT 26-JUN-1991 (first entry)
XX
DE Sequence encoding bovine inhibin B subunit.
XX
KW Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
XX
OS Bos taurus.
XX
FH Key Location/Qualifiers
FT CDS 1..516
FT /*tag= a
FT mat_peptide 517..867
FT /*tag= b
XX
PN WO8606076-A.
XX
PD 23-OCT-1986.
XX
PF 14-APR-1986; 86WO-AU00097.
XX
PR 20-DEC-1985; 85AU-0003961.
PR 18-APR-1985; 85AU-0000194.
PR 06-SEP-1985; 85AU-0002320.
PR 29-OCT-1985; 85AU-0003157.
PR 19-DEC-1985; 85AU-0003960.
PR 01-JAN-1986; 86AU-0059039.
PR 02-APR-1987; 87AU-0071015.
PR 05-MAY-1986; 86CN-0103459.
XX
PA (BIOT-) BIOTECHN AUSTR PTY.
PA (MONU) MONASH UNIV.
PA (HENR-) PRICE HENRY'S HOSPITAL.
PA (SVIN-) ST VINCENTS'S INST MED RE.
XX
PI Forage R, Stewart A, Robertson D, Dekretser DM;
XX
DR WPI; 1986-291647/44.
DR P-PSDB; AAP60518.
XX
PT New polynucleotide sequences and recombinant DNA - encoding
PT inhibin and synthetic peptides useful for affecting gonadal
PT function
XX
PS Claim 8; Fig 6; 71pp; English.
XX
CC DNA encoding inhibin and inhibin or part, analogues, homologues or
CC precursors thereof when produced by recombinant techniques are also
CC claimed, as well as pharmaceutical compositions thereof. These may
CC be used as an inhibin agonist, antagonist or eliciting an
CC antigenic response to affect gonadal function or reproductive
CC physiology.

```
XX
SQ   Sequence 958 BP; 242 A; 240 C; 302 G; 174 T; 0 other;

  Query Match             84.5%;  Score 26.2;  DB 7;  Length 958;
  Best Local Similarity   90.3%;  Pred. No. 0.094;
  Matches   28;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy      1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
          ||||||||||||||| ||||| || |||||||
Db    601 ATCATTGCTCCCTCCGGCTACCACGCCAACT 631


RESULT 13
AAN70317
ID   AAN70317 standard; cDNA; 3588 BP.
XX
AC   AAN70317;
XX
DT   09-APR-1991  (first entry)
XX
DE   Sequence encoding porcine inhibin beta-chain precursor beta-A.
XX
KW   Fertility control; contraception; hormone; spermatogenesis; ss.
XX
OS   Sus scrofa domestica.
XX
FH   Key             Location/Qualifiers
FT   CDS             34..957
FT                   /*tag= a
FT                   /product=hydrophobic signal sequence a pro-region
FT   mat_peptide     958..1307
FT                   /*tag= b
FT   polyA_signal    3551..3556
FT                   /*tag= c
XX
PN   EP222491-A.
XX
PD   20-MAY-1987.
XX
PF   02-OCT-1986;   86EP-0307586.
XX
PR   12-SEP-1986;   86US-0906729.
PR   03-OCT-1985;   85US-0783910.
PR   10-FEB-1986;   86US-0827710.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Mason AJ,  Seeburg PH;
XX
DR   WPI; 1987-137512/20.
DR   P-PSDB; AAP70200.
XX
PT   Recombinant human or porcine inhibin or activin - used for
PT   modulating clinical condition or reproductive physiology of
PT   animals.
XX
PS   Disclosure; Fig 1B; 48pp; English.
XX
CC   A compsn. comprising human or porcine inhibin which is completely
CC   free of unidentified or porcine proteins is claimed.  Also claimed
CC   are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
CC   chain.  Sequencing of inhibin-encoding cDNA has led to the
CC   identification of prodomain regions located N-terminal to the
CC   mature inhibin chains that represent coordinately expressed
CC   biologically active polypeptides.  The prodomain regions or
CC   prodomain immunogens are useful in monitoring preproinhibin
CC   processing in transformant cell culture or in experiments directed
CC   at modulating the climical condt. or reproductive physiology of
CC   animals.
XX
SQ   Sequence 3588 BP; 881 A; 986 C; 998 G; 723 T; 0 other;

  Query Match             74.2%;  Score 23;  DB 8;  Length 3588;
  Best Local Similarity   83.9%;  Pred. No. 2.8;
  Matches   26;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy      1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
          ||||| ||||| || ||||| || |||||||
Db   1042 ATCATCGCTCCGTCCGGCTACCACGCCAACT 1072


RESULT 14
AAQ10890
ID   AAQ10890 standard; DNA; 1667 BP.
XX
AC   AAQ10890;
XX
DT   13-MAY-1991  (first entry)
XX
DE   Encodes Xenopus Bone Morphogenetic Factor B9.
XX
KW   BMF; osteoporosis; fracture; cartilage; ss.
XX
OS   Xenopus laevis.
XX
FH   Key             Location/Qualifiers
FT   mat_peptide     651..1040
FT                   /*tag= a
FT                   /product= BMP B9
XX
PN   EP416578-A.
XX
PD   13-MAR-1991.
XX
PF   05-SEP-1990;   90EP-0117079.
XX
PR   20-JUL-1990;   90JP-0190774.
PR   06-SEP-1989;   89JP-0229250.
XX
PA   (TAKE ) TAKEDA CHEMICAL IND KK.
PA   (SCIT-) SCITECH RESEARCH CO.
XX
PI   Murakami K,  Ueno N,  Kato Y;
XX
DR   WPI; 1991-075112/11.
DR   P-PSDB; AAR10990.
XX
PT   Xenopus laevis bone morphogenetic protein and DNA encoding it -
PT   used in therapy of fracture or osteoporosis
XX
PS   Claim 5; Fig 2; 28pp; English.
XX
CC   A Xenopus laevis liver-derived DNA library in Charon 28 vector, was
CC   screened with a rat activin beta-A cDNA probe. Five clones were
CC   isolated, including clone B9. They were subcloned in pUC19 and used
CC   to transform competent E.coli HB101 cells. Transformant E.coli HB101/
CC   pXar9 coding for the B9 BMP was sequenced. See also AAQ10891-7.
XX
SQ   Sequence 1667 BP; 557 A; 295 C; 355 G; 450 T; 10 other;

  Query Match             69.0%;  Score 21.4;  DB 12;  Length 1667;
  Best Local Similarity   80.6%;  Pred. No. 12;
  Matches   25;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy      1 ATCATTGCTCCCTCTGGCTATCATGCCAACT 31
          ||||| || ||  ||||||| |||||||| |
Db    777 ATCATAGCACCTCCTGGCTACCATGCCAATT 807


RESULT 15
AAL07086
ID   AAL07086 standard; DNA; 9662 BP.
XX
AC   AAL07086;
XX
DT   21-NOV-2001  (first entry)
```

XX
DE Human reproductive system related antigen DNA SEQ ID NO: 9774.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01339.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.

PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 9774; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 9662 BP; 2746 A; 2172 C; 2097 G; 2647 T; 0 other;

Query Match 66.5%; Score 20.6; DB 22; Length 9662;
Best Local Similarity 85.2%; Pred. No. 36;
Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 3 CATTGCTCCCTCTGGCTATCATGCCAA 29
||| |||||||||||| || ||||||
Db 9175 CATGGCTCCCTCTGGCGGTCCTGCCAA 9201

Search completed: March 11, 2003, 00:17:27
Job time : 149.984 secs